SABS Valuation

SAB Biotherapeutics Inc

Add to Watchlist

Advanced Chart

2.220

0(0.000%)1D

Overview
Forecast
Valuation
Earnings

SABS Relative Valuation

SABS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SABS is overvalued; if below, it's undervalued.

Historical Valuation

SAB Biotherapeutics Inc (SABS) is now in the Fair zone, suggesting that its current forward PS ratio of 51.13 is considered Fairly compared with the five-year average of -9.65. The fair price of SAB Biotherapeutics Inc (SABS) is between 1.09 to 2.32 according to relative valuation methord.

Relative Value

Fair Zone

1.09-2.32

Current Price：2.22

Fair

-1.21

Trailing

Forward

0.00

EV/EBITDA

SAB Biotherapeutics Inc. (SABS) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

-0.52

EV/EBIT

SAB Biotherapeutics Inc. (SABS) has a current EV/EBIT of -0.52. The 5-year average EV/EBIT is -4.41. The thresholds are as follows: Strongly Undervalued below -17.65, Undervalued between -17.65 and -11.03, Fairly Valued between 2.21 and -11.03, Overvalued between 2.21 and 8.83, and Strongly Overvalued above 8.83. The current Forward EV/EBIT of -0.52 falls within the Historic Trend Line -Fairly Valued range.

51.13

SAB Biotherapeutics Inc. (SABS) has a current PS of 51.13. The 5-year average PS is 48.79. The thresholds are as follows: Strongly Undervalued below -143.68, Undervalued between -143.68 and -47.45, Fairly Valued between 145.03 and -47.45, Overvalued between 145.03 and 241.26, and Strongly Overvalued above 241.26. The current Forward PS of 51.13 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

SAB Biotherapeutics Inc. (SABS) has a current P/OCF of 0.00. The 5-year average P/OCF is 1.95. The thresholds are as follows: Strongly Undervalued below -119.32, Undervalued between -119.32 and -58.69, Fairly Valued between 62.58 and -58.69, Overvalued between 62.58 and 123.21, and Strongly Overvalued above 123.21. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-0.48

P/FCF

SAB Biotherapeutics Inc. (SABS) has a current P/FCF of -0.48. The 5-year average P/FCF is -7.15. The thresholds are as follows: Strongly Undervalued below -33.41, Undervalued between -33.41 and -20.28, Fairly Valued between 5.98 and -20.28, Overvalued between 5.98 and 19.11, and Strongly Overvalued above 19.11. The current Forward P/FCF of -0.48 falls within the Historic Trend Line -Fairly Valued range.

SAB Biotherapeutics Inc (SABS) has a current Price-to-Book (P/B) ratio of 1.72. Compared to its 3-year average P/B ratio of 1.18 , the current P/B ratio is approximately 45.70% higher. Relative to its 5-year average P/B ratio of 3.02, the current P/B ratio is about -43.17% higher. SAB Biotherapeutics Inc (SABS) has a Forward Free Cash Flow (FCF) yield of approximately -134.42%. Compared to its 3-year average FCF yield of -102.43%, the current FCF yield is approximately 31.23% lower. Relative to its 5-year average FCF yield of -71.56% , the current FCF yield is about 87.86% lower.

1.72

P/B

Median3y

1.18

Median5y

3.02

-134.42

FCF Yield

Median3y

-102.43

Median5y

-71.56

Competitors Valuation Multiple

The average P/S ratio for SABS's competitors is 23.56, providing a benchmark for relative valuation. SAB Biotherapeutics Inc Corp (SABS) exhibits a P/S ratio of 51.13, which is 117.00% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

SABS.O

SAB Biotherapeutics Inc

CytoMed Therapeutics Ltd

39.59

20.77M

SONN.O

Sonnet Biotherapeutics Holdings Inc

Performance Decomposition

Market capitalization of SABS increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of SABS in the past 1 year is driven by Unknown.